Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models

被引：243

作者：

Kim, Hyoung ^{[1
]}

George, Erin ^{[1
]}

Ragland, Ryan L. ^{[2
]}

Rafail, Stavros ^{[1
]}

Zhang, Rugang ^{[3
]}

Krepler, Clemens ^{[3
]}

Morgan, Mark A. ^{[1
]}

Herlyn, Meenhard ^{[3
]}

Brown, Eric J. ^{[2
]}

Simpkins, Fiona ^{[1
]}

机构：

[1] Univ Penn, Dept Obstet & Gynecol, Div Gynecol Oncol, Penn Ovarian Canc Res Ctr, Philadelphia, PA 19104 USA

[2] Univ Penn, Canc Biol, Philadelphia, PA 19104 USA

[3] Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA

来源：

CLINICAL CANCER RESEARCH | 2017年 / 23卷 / 12期

关键词：

REPLICATION FORK COLLAPSE; SYNTHETIC LETHALITY; RANDOMIZED PHASE-2; CELL-CYCLE; ATR; CHK1; CHECKPOINT; OLAPARIB; THERAPY; PHOSPHORYLATION;

D O I：

10.1158/1078-0432.CCR-16-2273

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: PARP inhibition (PARPi) has modest clinical activity in recurrent BRCA-mutant (BRCA(MUT)) high-grade serous ovarian cancers (HGSOC). We hypothesized that PARPi increases dependence on ATR/CHK1 such that combination PARPi with ATR/CHK1 blockade results in increased cell death and tumor regression. Experimental Design: Effects of PARPi (olaparib), CHK1 inhibition (CHK1i; MK8776), or ATR inhibition (ATRi; AZD6738) alone or in combination on survival, colony formation, cell cycle, genome instability, and apoptosis were evaluated in BRCA1/2(MUT) HGSOC cells. Tumor growth in vivo was evaluated using a BRCA2(MUT) patient-derived xenograft (PDX) model. Results: PARPi monotherapy resulted in a decrease in BRCA(MUT) cell survival, colony formation and suppressed but did not eliminate tumor growth at the maximum tolerated dose(MTD) in a BRCA2(MUT) PDX. PARPi treatment increased pATR and pCHK1, indicating activation of the ATR-CHK1 fork protection pathway is relied upon for genome stability under PARPi. Indeed, combination of ATRi orCHK1i with PARPi synergistically decreased survival and colony formation compared with single-agent treatments in BRCA(MUT) cells. Notably, PARPi led to G2 phase accumulation, and the addition of ATRi or CHK1i released cells from G2 causing premature mitotic entry with increased chromosomal aberrations and apoptosis. Moreover, the combinations of PARPi with ATRi or CHK1i were synergistic in causing tumor suppression in a BRCA2(MUT) PDX with the PARPi-ATRi combination inducing tumor regression and in most cases, complete remission. Conclusions: PARPi causes increased reliance on ATR/CHK1 for genome stability, and combination PARPi with ATR/CHK1i is more effective than PARPi alone in reducing tumor burden in BRCA(MUT) models. (C) 2016 AACR.

引用

页码：3097 / 3108

页数：12

共 45 条

[1] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial [J].

Audeh, M. William ;

Carmichael, James ;

Penson, Richard T. ;

Friedlander, Michael ;

Powell, Bethan ;

Bell-McGuinn, Katherine M. ;

Scott, Clare ;

Weitzel, Jeffrey N. ;

Oaknin, Ana ;

Loman, Niklas ;

Lu, Karen ;

Schmutzler, Rita K. ;

Matulonis, Ursula ;

Wickens, Mark ;

Tutt, Andrew .

LANCET, 2010, 376 (9737) :245-251

[2] Chk1 and Chk2 kinases in checkpoint control and cancer [J].

Bartek, J ;

Lukas, J .

CANCER CELL, 2003, 3 (05) :421-429

[3] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[4]

Brown EJ, 2000, GENE DEV, V14, P397

[5] Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance [J].

Brown, EJ ;

Baltimore, D .

GENES & DEVELOPMENT, 2003, 17 (05) :615-628

[6] Protein ADP-ribosylation and the cellular response to DNA strand breaks [J].

Caldecott, K. W. .

DNA REPAIR, 2014, 19 :108-113

[7] CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors [J].

Chen, Clark C. ;

Kennedy, Richard D. ;

Sidi, Samuel ;

Look, A. Thomas ;

D'Andrea, Alan .

MOLECULAR CANCER, 2009, 8

[8] Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics [J].

Chen, Zehan ;

Xiao, Zhan ;

Gul, Wen-zhen ;

Xue, John ;

Bui, Mai H. ;

Kovar, Peter ;

Li, Gaoquan ;

Wang, Gary ;

Tao, Zhi-Fu ;

Tong, Yunsong ;

Lin, Nan-Horng ;

Sham, Hing L. ;

Wang, Jean Y. J. ;

Sowin, Thomas J. ;

Rosenberg, Saul H. ;

Zhang, Haiying .

INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (12) :2784-2794

[9] ATR phosphorylates SMARCAL1 to prevent replication fork collapse [J].

Couch, Frank B. ;

Bansbach, Carol E. ;

Driscoll, Robert ;

Luzwick, Jessica W. ;

Glick, Gloria G. ;

Betous, Remy ;

Carroll, Clinton M. ;

Jung, Sung Yun ;

Qin, Jun ;

Cimprich, Karlene A. ;

Cortez, David .

GENES & DEVELOPMENT, 2013, 27 (14) :1610-1623

[10]

Dillon M., 2016, J CLIN ONCOL S, V34

← 1 2 3 4 5 →